Skip to main content
SpringerLink
Log in

Epidemiology of PTLD

  • Chapter
Post-Transplant Lymphoproliferative Disorders

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004;4(2):222

    Article  PubMed  Google Scholar 

  2. Webster AC, Craig JC, Simpson JM, Jones MP, Chapman JR. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients. Am J Transplant. 2007;7(9):2140

    Article  PubMed  CAS  Google Scholar 

  3. Srisawat N, Avihingsanon A, Praditpornsilpa K, Jiamjarasrangsi W, Eiam-Ong S, Avihingsanon Y. A prevalence of posttransplantation cancers compared with cancers in people with human immunodeficiency virus/acquired immunodeficiency syndrome after highly active antiretrovi-ral therapy. Transplant Proc. 2008;40(8):2677

    Article  PubMed  CAS  Google Scholar 

  4. Boubenider S, Hiesse C, Goupy C, Kriaa F, Marchand S, Charpentier B. Incidence and consequences of post-transplantation lymphoproliferative disorders. J Nephrol. 1997;10(3):136

    PubMed  CAS  Google Scholar 

  5. Younes BS, McDiarmid SV, Martin MG, et al. The effect of immunosuppression on posttrans-plant lymphoproliferative disease in pediatric liver transplant patients. Transplantation. 2000;70 (1):94

    PubMed  CAS  Google Scholar 

  6. Dharnidharka VR, Sullivan EK, Stablein DM, Tejani AH, Harmon WE. Risk factors for post-transplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation. 2001;71(8):1065

    Article  PubMed  CAS  Google Scholar 

  7. Dharnidharka VR, Ho PL, Stablein DM, Harmon WE, Tejani AH. Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant. 2002;6(5):396

    Article  PubMed  CAS  Google Scholar 

  8. Kremers WK, Devarbhavi HC, Wiesner RH, Krom RA, Macon WR, Habermann TM. Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am J Transplant. 2006;6(5 Pt 1):1017

    Article  PubMed  CAS  Google Scholar 

  9. Harmon WE, Dharnidharka VR. Lymphoproliferative disease in children. Transplant Proc. 1999;31(2B):1268

    Article  PubMed  CAS  Google Scholar 

  10. Alfrey EJ, Friedman AL, Grossman RA, et al. A recent decrease in the time to development of monomorphous and polymorphous posttransplant lymphoproliferative disorder. Transplantation. 1992;54(2):250

    Article  PubMed  CAS  Google Scholar 

  11. Ciancio G, Siquijor AP, Burke GW, et al. Post-transplant lymphoproliferative disease in kidney transplant patients in the new immunosuppressive era. Clin Transplant. 1997;11(3):243

    PubMed  CAS  Google Scholar 

  12. Dharnidharka VR, Tejani AH, Ho PL, Harmon WE. Post-transplant lymphoproliferative disorder in the United States: young Caucasian males are at highest risk. Am J Transplant. 2002;2(10):993

    Article  PubMed  Google Scholar 

  13. McDonald RA, Smith JM, Ho M, et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant. 2008;8 (5):984

    Article  PubMed  CAS  Google Scholar 

  14. McDiarmid SV, Jordan S, Lee GS, et al. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation. 1998;66(12):1604

    Article  PubMed  CAS  Google Scholar 

  15. Faull RJ, Hollett P, McDonald SP. Lymphoproliferative disease after renal transplantation in Australia and New Zealand. Transplantation. 2005;80(2):193

    Article  PubMed  Google Scholar 

  16. Leblond V, Sutton L, Dorent R, et al. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol. 1995;13(4):961

    PubMed  CAS  Google Scholar 

  17. Caillard S, Lelong C, Pessione F, Moulin B. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry. Am J Transplant. 2006;6(11):2735

    Article  PubMed  CAS  Google Scholar 

  18. Patel H, Vogl DT, Aqui N, et al. Posttransplant lymphoproliferative disorder in adult liver transplant recipients: a report of seventeen cases. Leuk Lymphoma. 2007;48(5):885

    Article  PubMed  Google Scholar 

  19. Saadat A, Einollahi B, Ahmadzad-Asl MA, et al. Posttransplantation lymphoproliferative disorders in renal transplant recipients: report of over 20 years of experience. Transplant Proc. 2007;39(4):1071

    Article  PubMed  CAS  Google Scholar 

  20. Cacciarelli TV, Green M, Jaffe R, et al. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. Transplantation. 1998;66(8):1047

    Article  PubMed  CAS  Google Scholar 

  21. Duvoux C, Pageaux GP, Vanlemmens C, et al. Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients. Transplantation. 2002;74(8):1103

    Article  PubMed  Google Scholar 

  22. Fernandez MC, Bes D, De Davila M, et al. Post-transplant lymphoproliferative disorder after pediatric liver transplantation: characteristics and outcome. Pediatr Transplant. 2009;13(3):307

    Article  PubMed  Google Scholar 

  23. Caillard S, Dharnidharka V, Agodoa L, Bohen E, Abbott K. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation. 2005;80(9):1233

    Article  PubMed  CAS  Google Scholar 

  24. Chang RS, Lewis JP, Reynolds RD, Sullivan MJ, Neuman J. Oropharyngeal excretion of Epstein-Barr virus by patients with lymphoproliferative disorders and by recipients of renal homografts. Ann Intern Med. 1978;88(1):34

    Article  PubMed  CAS  Google Scholar 

  25. Marker SC, Ascher NL, Kalis JM, Simmons RL, Najarian JS, Balfour HH Jr. Epstein-Barr virus antibody responses and clinical illness in renal transplant recipients. Surgery. 1979;85(4):433

    PubMed  CAS  Google Scholar 

  26. Hanto DW, Frizzera G, Purtilo DT, et al. Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res. 1981;41 (11 Pt 1):4253

    PubMed  CAS  Google Scholar 

  27. Hanto DW, Sakamoto K, Purtilo DT, Simmons RL, Najarian JS. The Epstein-Barr virus in the pathogenesis of posttransplant lymphoproliferative disorders. Clinical, pathologic, and viro-logic correlation. Surgery. 1981;90(2):204

    PubMed  CAS  Google Scholar 

  28. Walker RC, Paya CV, Marshall WF, et al. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant. 1995;14(2):214

    PubMed  CAS  Google Scholar 

  29. Walker RC, Marshall WF, Strickler JG, et al. Pretransplantation assessment of the risk of lym-phoproliferative disorder. Clin Infect Dis. 1995;20(5):1346

    Article  PubMed  CAS  Google Scholar 

  30. Manez R, Breinig MC, Linden P, et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J Infect Dis. 1997;176(6):1462

    Article  PubMed  CAS  Google Scholar 

  31. Newell KA, Alonso EM, Whitington PF, et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation. 1996;62(3):370

    Article  PubMed  CAS  Google Scholar 

  32. Kirk AD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant. 2007;7(11):2619

    Article  PubMed  CAS  Google Scholar 

  33. Sundin M, Le Blanc K, Ringden O, et al. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica. 2006;91(8):1059

    PubMed  Google Scholar 

  34. Bakker NA, van Imhoff GW, Verschuuren EA, et al. HLA antigens and post renal transplant lymphoproliferative disease: HLA-B matching is critical. Transplantation. 2005;80(5):595

    Article  PubMed  CAS  Google Scholar 

  35. Pourfarziani V, Einollahi B, Taheri S, Nemati E, Nafar M, Kalantar E. Associations of Human Leukocyte Antigen (HLA) haplotypes with risk of developing lymphoproliferative disorders after renal transplantation. Ann Transplant. 2007;12(4):16

    PubMed  Google Scholar 

  36. Wheless SA, Gulley ML, Raab-Traub N, et al. Post-transplantation lymphoproliferative disease: Epstein Barr virus DNA levels, HLA A3 and survival. Am J Respir Crit Care Med. 2008; 178(10):1060

    Article  PubMed  CAS  Google Scholar 

  37. McLaughlin K, Wajstaub S, Marotta P, et al. Increased risk for posttransplant lymphoprolifera-tive disease in recipients of liver transplants with hepatitis C. Liver Transpl. 2000;6(5):570

    Article  PubMed  CAS  Google Scholar 

  38. Shpilberg O, Wilson J, Whiteside TL, Herberman RB. Pre-transplant immunological profile and risk factor analysis of post-transplant lymphoproliferative disease development: the results of a nested matched case-control study. The University of Pittsburgh PTLD Study Group. Leuk Lymphoma. 1999;36(1–2):109

    CAS  Google Scholar 

  39. Newell KA, Alonso EM, Kelly SM, Rubin CM, Thistlethwaite JR Jr., Whitington PF. Association between liver transplantation for Langerhans cell histiocytosis, rejection, and development of posttransplant lymphoproliferative disease in children. J Pediatr. 1997;131(1 Pt 1):98

    PubMed  CAS  Google Scholar 

  40. Quintini C, Kato T, Gaynor JJ, et al. Analysis of risk factors for the development of posttrans-plant lymphoprolipherative disorder among 119 children who received primary intestinal transplants at a single center. Transplant Proc. 2006;38(6):1755

    Article  PubMed  CAS  Google Scholar 

  41. Finn L, Reyes J, Bueno J, Yunis E. Epstein-Barr virus infections in children after transplantation of the small intestine. Am J Surg Pathol. 1998;22(3):299

    Article  PubMed  CAS  Google Scholar 

  42. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoprolifera-tive disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med. 1990;323(25):1723

    Article  PubMed  CAS  Google Scholar 

  43. Dharnidharka VR, Harmon WE. Management of pediatric postrenal transplantation infections. Semin Nephrol. 2001;21(5):521

    Article  PubMed  CAS  Google Scholar 

  44. Penn I. Cancers following cyclosporine therapy. Transplantation. 1987;43(1):32

    Article  PubMed  CAS  Google Scholar 

  45. Penn I. Neoplastic complications of transplantation. Semin Respir Infect. 1993;8(3):233

    PubMed  CAS  Google Scholar 

  46. Guthery SL, Heubi JE, Bucuvalas JC, et al. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. Transplantation. 2003;75(7):987

    Article  PubMed  CAS  Google Scholar 

  47. Opelz G, Naujokat C, Daniel V, Terness P, Dohler B. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation. 2006;81(9):1227

    Article  PubMed  CAS  Google Scholar 

  48. Katz BZ, Pahl E, Crawford SE, et al. Case-control study of risk factors for the development of post-transplant lymphoproliferative disease in a pediatric heart transplant cohort. Pediatr Transplant. 2007;11(1):58

    Article  PubMed  CAS  Google Scholar 

  49. Dharnidharka VR, Stevens G. Risk for post-transplant lymphoproliferative disorder after poly-clonal antibody induction in kidney transplantation. Pediatr Transplant. 2005;9:622

    Article  PubMed  Google Scholar 

  50. Hardinger KL, Rhee S, Buchanan P, et al. A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results. Transplantation. 2008;86(7):947

    Article  PubMed  CAS  Google Scholar 

  51. Bustami RT, Ojo AO, Wolfe RA, et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant. 2004;4(1):87

    Article  PubMed  Google Scholar 

  52. Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation. 2003; 76(9):1289

    Article  PubMed  CAS  Google Scholar 

  53. Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R, et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation. 1995;59(4):524

    PubMed  CAS  Google Scholar 

  54. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and metaregression of randomised trial data. BMJ. 2005;331(7520):810

    Article  Google Scholar 

  55. Birkeland SA, Hamilton-Dutoit S. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? Transplantation. 2003;76(6):984

    Article  PubMed  CAS  Google Scholar 

  56. Funch DP, Ko HH, Travasso J, et al. Posttransplant lymphoproliferative disorder among renal transplant patients in relation to the use of mycophenolate mofetil. Transplantation. 2005;80(9):1174

    Article  PubMed  Google Scholar 

  57. Robson R, Cecka JM, Opelz G, Budde M, Sacks S. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant. 2005;5(12):2954

    Article  PubMed  CAS  Google Scholar 

  58. Majewski M, Korecka M, Kossev P, et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci U S A. 2000;97(8):4285

    Article  PubMed  CAS  Google Scholar 

  59. Nepomuceno RR, Balatoni CE, Natkunam Y, Snow AL, Krams SM, Martinez OM. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res. 2003;63(15):4472

    PubMed  CAS  Google Scholar 

  60. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppres-sion with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation. 2005;80(7):883

    Article  PubMed  CAS  Google Scholar 

  61. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med. 2005;353(8):770

    Article  PubMed  CAS  Google Scholar 

  62. Vincenti F, Mendez R, Pescovitz M, et al. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant. 2007;7(7):1770

    Article  PubMed  CAS  Google Scholar 

  63. Hebert D, Sullivan EK. Malignancy and post transplant lymphoproliferative disorder (PTLD) in pediatric renal transplant recipients: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant. 1998;2(S 1):107:57A

    Google Scholar 

  64. Hayashi RJ, Kraus MD, Patel AL, et al. Posttransplant lymphoproliferative disease in children: correlation of histology to clinical behavior. J Pediatr Hematol Oncol. 2001;23(1):14

    Article  PubMed  CAS  Google Scholar 

  65. Buell JF, Gross TG, Hanaway MJ, et al. Posttransplant lymphoproliferative disorder: signifi-cance of central nervous system involvement. Transplant Proc. 2005;37(2):954

    Article  PubMed  CAS  Google Scholar 

  66. Johnson SR, Cherikh WS, Kauffman HM, Pavlakis M, Hanto DW. Retransplantation after post-transplant lymphoproliferative disorders: an OPTN/UNOS database analysis. Am J Transplant. 2006;6(11):2743

    Article  PubMed  CAS  Google Scholar 

  67. Cockfield SM, Preiksaitis JK, Jewell LD, Parfrey NA. Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center. Transplantation. 1993;56(1):88

    Article  PubMed  CAS  Google Scholar 

  68. Mendoza F, Kunitake H, Laks H, Odim J. Post-transplant lymphoproliferative disorder following pediatric heart transplantation. Pediatr Transplant. 2006;10(1):60

    Article  PubMed  Google Scholar 

  69. Allen UD, Farkas G, Hebert D, et al. Risk factors for post-transplant lymphoproliferative disorder in pediatric patients: a case-control study. Pediatr Transplant. 2005;9(4):450

    Article  PubMed  Google Scholar 

  70. Ng VL, Fecteau A, Shepherd R, et al. Outcomes of 5-year survivors of pediatric liver transplantation: report on 461 children from a north american multicenter registry. Pediatrics. 2008;122 (6):e1128.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pediatric Nephrology, University of Florida College of Medicine, Gainesville, FL, USA

    Vikas R. Dharnidharka

Authors
  1. Vikas R. Dharnidharka
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pediatric Kidney Transplantation, Shands Hospital at UF, University of Florida College of Medicine Medical Director, Gainesville, Florida, USA

    Vikas R. Dharnidharka (Associate Professor and Chief Fellowship Program Director Division of Pediatric Nephrology) (Associate Professor and Chief Fellowship Program Director Division of Pediatric Nephrology)

  2. Division of Infectious Diseases Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA

    Michael Green (Professor of Pediatrics and Surgery) (Professor of Pediatrics and Surgery)

  3. Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA

    Steven A. Webber (Professor of Pediatrics, Chief, Division of Cardiology Co-Director, Heart Center Medical Director, Pediatric Heart and Heart-Lung Transplantation) (Professor of Pediatrics, Chief, Division of Cardiology Co-Director, Heart Center Medical Director, Pediatric Heart and Heart-Lung Transplantation)

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Dharnidharka, V.R. (2010). Epidemiology of PTLD. In: Dharnidharka, V.R., Green, M., Webber, S.A. (eds) Post-Transplant Lymphoproliferative Disorders. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-01653-0_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-01653-0_3

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-01652-3

  • Online ISBN: 978-3-642-01653-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation